Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Receivables - Net (2016 - 2025)

Historic Receivables - Net for Ani Pharmaceuticals (ANIP) over the last 16 years, with Q3 2025 value amounting to $252.6 million.

  • Ani Pharmaceuticals' Receivables - Net rose 2864.93% to $252.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $252.6 million, marking a year-over-year increase of 2864.93%. This contributed to the annual value of $221.7 million for FY2024, which is 3680.12% up from last year.
  • As of Q3 2025, Ani Pharmaceuticals' Receivables - Net stood at $252.6 million, which was up 2864.93% from $225.7 million recorded in Q2 2025.
  • In the past 5 years, Ani Pharmaceuticals' Receivables - Net ranged from a high of $252.6 million in Q3 2025 and a low of $91.9 million during Q1 2021
  • Moreover, its 5-year median value for Receivables - Net was $166.1 million (2024), whereas its average is $165.9 million.
  • Per our database at Business Quant, Ani Pharmaceuticals' Receivables - Net soared by 6234.57% in 2022 and then plummeted by 395.2% in 2024.
  • Ani Pharmaceuticals' Receivables - Net (Quarter) stood at $128.5 million in 2021, then grew by 28.72% to $165.4 million in 2022, then fell by 2.03% to $162.1 million in 2023, then skyrocketed by 36.8% to $221.7 million in 2024, then increased by 13.93% to $252.6 million in 2025.
  • Its last three reported values are $252.6 million in Q3 2025, $225.7 million for Q2 2025, and $220.3 million during Q1 2025.